Biotech Stocks Showcase Significant Upside Potential

Viking Therapeutics has received a reissued "buy" rating from HC Wainwright with a price target of $102, indicating potential upside. Several analysts have provided varying price targets, with a consensus rating of "Buy" and an average target of $106.75. Despite reporting a quarterly loss, Viking's performance exceeded expectations, prompting optimism among some analysts. Meanwhile, JPMorgan indicates that biotech stocks, including Viking, may see considerable upside as market conditions improve post-rate cuts by the Fed. Goldman Sachs also highlights biotech as an underrated opportunity, particularly in light of the recent interest rate changes which could benefit companies reliant on projected future profits. Overall, the biotech sector is showing signs of recovery after a challenging period, with analysts recommending a focus on companies with growth potential.